|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
$0.38 0.00 (0.00%) as of 4:30 Mon 8/21
|
|
Download |
|
|
| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
8,423,000 |
| Market
Cap: |
3.20(M) |
| Last
Volume: |
1,933,173 |
Avg
Vol: |
663,431 |
| 52
Week Range: |
$0.38 - $1.85 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Idera Pharmaceuticals is a biopharmaceutical company focused on the clinical development, and the commercialization, of drug candidates for rare disease indications characterized by patient populations with unmet medical needs. Co.'s focus is to identify and acquire rights to development and commercial stage rare disease programs through new business development opportunities, including additional alternatives. Co. is evaluating intratumoral tilsotolimod in combination with nivolumab, an anti-Progressive Disease 1 antibody marketed as Opdivo® by Bristol Myers Squibb Company, and ipilimumab for the treatment of multiple solid tumors in a multicohort trial.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
26,965 |
26,965 |
| Total Buy Value |
$0 |
$0 |
$38,290 |
$38,290 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
0 |
0 |
226,310 |
273,476 |
| Total Sell Value |
$0 |
$0 |
$333,274 |
$420,198 |
| Total People Sold |
0 |
0 |
4 |
4 |
| Total Sell Transactions |
0 |
0 |
8 |
9 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Schafer Carol |
Director |
– • – |
2020-04-01 |
4 |
A |
$1.28 |
$13,610 |
D/D |
10,633 |
31,076 |
|
- |
|
| Goldberg Mark Alan |
Director |
– • – |
2020-04-01 |
4 |
A |
$1.28 |
$13,734 |
D/D |
10,730 |
20,730 |
|
- |
|
| Pien Howard H |
Director |
– • – |
2020-04-01 |
4 |
A |
$1.28 |
$12,372 |
D/D |
9,666 |
32,856 |
|
- |
|
| Zein Youssef El |
10% Owner |
– – • |
2020-01-29 |
4 |
S |
$1.76 |
$30,438 |
I/I |
(17,250) |
3,254,442 |
|
-17% |
|
| Zein Youssef El |
10% Owner |
– – • |
2020-01-28 |
4 |
S |
$1.76 |
$22,081 |
I/I |
(12,532) |
3,271,692 |
|
-12% |
|
| Zein Youssef El |
10% Owner |
– – • |
2020-01-27 |
4 |
S |
$1.77 |
$26,550 |
I/I |
(15,000) |
3,284,224 |
|
-3% |
|
| Lim Bryant David |
SVP and General Counsel |
• – – |
2020-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
41,240 |
|
- |
|
| Yingling Jonathan Michael |
Chief Scientific Officer |
• – – |
2020-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
36,358 |
|
- |
|
| Fletcher Robert C. |
Sr. VP, Bus. Dev. & Strategy |
• – – |
2020-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
36,485 |
|
- |
|
| Kirby John J. |
Chief Financial Officer |
• – – |
2020-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
36,437 |
|
- |
|
| Tarka Elizabeth Ann |
Chief Medical Officer |
• – – |
2020-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
20,000 |
|
- |
|
| Milano Vincent |
President & CEO |
• • – |
2020-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
37,000 |
123,560 |
|
- |
|
| Yingling Jonathan Michael |
Chief Scientific Officer |
• – – |
2020-01-07 |
4/A |
AS |
$1.78 |
$3,101 |
D/D |
(1,742) |
16,358 |
|
- |
|
| Lim Bryant David |
SVP and General Counsel |
• – – |
2020-01-07 |
4/A |
AS |
$1.78 |
$2,854 |
D/D |
(1,603) |
21,240 |
|
- |
|
| Kirby John J. |
Chief Financial Officer |
• – – |
2020-01-07 |
4/A |
AS |
$1.78 |
$1,622 |
D/D |
(911) |
16,437 |
|
- |
|
| Fletcher Robert C. |
Sr. VP, Bus. Dev. & Strategy |
• – – |
2020-01-07 |
4/A |
AS |
$1.78 |
$2,875 |
D/D |
(1,615) |
16,485 |
|
- |
|
| Milano Vincent |
President & CEO |
• • – |
2020-01-07 |
4/A |
AS |
$1.78 |
$5,352 |
D/D |
(3,006) |
86,560 |
|
- |
|
| Milano Vincent |
President & CEO |
• • – |
2020-01-07 |
4 |
S |
$1.78 |
$5,352 |
D/D |
(3,006) |
86,560 |
|
1% |
|
| Kirby John J. |
Chief Financial Officer |
• – – |
2020-01-07 |
4 |
S |
$1.78 |
$1,622 |
D/D |
(911) |
16,437 |
|
1% |
|
| Yingling Jonathan Michael |
Chief Scientific Officer |
• – – |
2020-01-07 |
4 |
S |
$1.78 |
$3,101 |
D/D |
(1,742) |
16,358 |
|
1% |
|
| Lim Bryant David |
SVP and General Counsel |
• – – |
2020-01-07 |
4 |
S |
$1.78 |
$2,854 |
D/D |
(1,603) |
21,240 |
|
1% |
|
| Fletcher Robert C. |
Sr. VP, Bus. Dev. & Strategy |
• – – |
2020-01-07 |
4 |
S |
$1.78 |
$2,875 |
D/D |
(1,615) |
16,485 |
|
1% |
|
| Pien Howard H |
Director |
– • – |
2020-01-02 |
4 |
A |
$1.85 |
$12,562 |
D/D |
6,790 |
23,190 |
|
- |
|
| Dougherty Michael R |
Director |
– • – |
2020-01-02 |
4 |
A |
$1.85 |
$13,018 |
D/D |
7,037 |
11,156 |
|
- |
|
| Zein Youssef El |
10% Owner |
– – • |
2019-11-08 |
4 |
S |
$2.44 |
$21,960 |
I/I |
(9,000) |
3,299,224 |
|
- |
|
234 Records found
|
|
Page 4 of 10 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
